foscarnet has been researched along with zalcitabine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (11.54) | 18.7374 |
| 1990's | 13 (50.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 4 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corbett, TH; Court, BA; Kessel, D; Phadtare, S; Renis, HE; Zimlicka, J | 1 |
| De Clercq, E | 1 |
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Ayisi, NK; Gupta, SV; Qualtiere, LF | 1 |
| Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
| Cotton, P | 1 |
| Darby, G; Larder, BA; Richman, DD | 1 |
| Richman, DD | 1 |
| Caliendo, AM; Hirsch, MS | 1 |
| Berthillon, P; Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Hantz, O; Mourier, N; Trépo, C; Turin, F | 1 |
| Morris, DJ | 1 |
| Gobert, JM; North, TW; Remington, KM; Zhu, YQ | 1 |
| Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Kraus, JL; Mourier, N | 1 |
| Brun-Vezinet, F; Pépin, JM; Simon, F | 1 |
| Anderson, KP; Azad, RF; Brown-Driver, V; Buckheit, RW | 1 |
| Cox, S; Harmenberg, J; Palmer, S | 1 |
| Fujiwara, T; Kaneko, H; Mori, S; Shigeta, S | 1 |
| Mills, R; Wu, GZ | 1 |
6 review(s) available for foscarnet and zalcitabine
| Article | Year |
|---|---|
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Antibodies, Viral; Antigens, Viral; Aurintricarboxylic Acid; Deltaretrovirus; Deoxycytidine; Foscarnet; Genes, Viral; Glycoproteins; Humans; Interferons; Male; Phosphonoacetic Acid; Retroviridae Infections; Reverse Transcriptase Inhibitors; Ribavirin; RNA, Viral; Suramin; Thymidine; Transcription, Genetic; Viral Proteins; Virus Replication; Zalcitabine; Zidovudine | 1986 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine | 1993 |
1 trial(s) available for foscarnet and zalcitabine
| Article | Year |
|---|---|
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Evaluation; Foscarnet; Humans; Opportunistic Infections; Phosphonoacetic Acid; Zalcitabine; Zidovudine | 1988 |
20 other study(ies) available for foscarnet and zalcitabine
| Article | Year |
|---|---|
Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
Topics: Adenosine Deaminase; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Friend murine leukemia virus; HIV-1; HIV-2; Humans; Indicators and Reagents; Leukemia L1210; Mice; Molecular Structure; Nucleosides; Rauscher Virus; Structure-Activity Relationship | 1991 |
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine | 1991 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Zalcitabine | 1990 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Foscarnet; HeLa Cells; HIV; HIV Core Protein p24; Humans; Microbial Sensitivity Tests; Phosphonoacetic Acid; Retroviridae Proteins; Reverse Transcriptase Inhibitors; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1989 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
Synthesis and antiviral activity of new carbonylphosphonate 2',3'-dideoxy-3'-thiacytidine conjugates.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Drug Evaluation, Preclinical; Ducks; Foscarnet; Giant Cells; Hepatitis B Virus, Duck; HIV-1; Humans; Lamivudine; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Structure-Activity Relationship; Thionucleosides; Zalcitabine | 1994 |
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine | 1994 |
Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates.
Topics: Antiviral Agents; Foscarnet; HIV-1; Lamivudine; Phosphonoacetic Acid; Prodrugs; Structure-Activity Relationship; Virus Replication; Zalcitabine | 1994 |
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cytomegalovirus; Drug Interactions; Foscarnet; Ganciclovir; HIV-1; Humans; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; RNA, Viral; Thionucleotides; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine | 1996 |
[Evaluation of antiviral agents for adenovirus using the MTT method in vitro].
Topics: Acyclovir; Adenoviridae; Antiviral Agents; Cells, Cultured; Cidofovir; Cytosine; Drug Evaluation, Preclinical; Foscarnet; Humans; Organophosphonates; Organophosphorus Compounds; Zalcitabine | 2000 |
Synthesis and evaluation of novel prodrugs of foscarnet and dideoxycytidine with a universal carrier compound comprising a chemiluminescent and a photochromic conjugate.
Topics: Animals; Drug Carriers; Drug Evaluation, Preclinical; Foscarnet; HIV-1; Humans; Luminescent Agents; Macrophages; Mice; Prodrugs; Zalcitabine | 2004 |